Article | April 5, 2017

Why the Shift From Batch To Continuous For Pharmaceutical Oral Solid Manufacturing Is Now Upon Us

Source: CRB
Why the Shift From Batch To Continuous For Pharmaceutical Oral Solid Manufacturing Is Now Upon Us

By David DiProspero, Director of Pharmaceutical Process Technology, CRB

Why the Shift from Batch to Continuous for Pharmaceutical Oral Solid Dosage Form Tablet Manufacture is Now Upon Us

“Although it is not easy for drug manufacturers to transition from batch to continuous manufacturing, there are significant rewards.  FDA encourages others in the pharmaceutical industry to consider similar efforts.”  Lawrence Yu, Ph.D. - FDA Deputy Director, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research